Citi upgraded Hologic (HOLX) to Buy from Neutral with a price target of $80, up from $60. The firm says the as a recent potential buyout report has increased interest in the the shares while fiscal 2025 estimates are reasonable. Street estimates are now appropriately reflecting the current demand trends and possible tariff implications, while Hologic shares are trading at a discount to both historical averages and the peer group, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- USPSTF ruling ‘marks the turn’ for Exact Sciences shares, says Evercore ISI
- Early notable gainers among liquid option names on May 28th
- Hologic’s Hold Rating: Balancing Potential and Risks Amidst Market Challenges
- Takeout offer validates Hologic at attractive valuation, says Raymond James
- Hologic jumps 22% after FT says TPG, Blackstone made buyout offer